Effect of dexmedetomidine anesthesia on perioperative levels of TNF-α and IL-6 in patients with ovarian cancer

Liu,Maodong; Yi,Yusheng; Zhao,Mingqiang

doi:10.3892/ol.2019.10247

Effect of dexmedetomidine anesthesia on perioperative levels of TNF-α and IL-6 in patients with ovarian cancer

Authors:
- Maodong Liu
- Yusheng Yi
- Mingqiang Zhao
View Affiliations

Affiliations: Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Pain Management, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Anesthesiology, Qingdao Center Hospital, Qingdao, Shandong 266000, P.R. China
Published online on: April 12, 2019 https://doi.org/10.3892/ol.2019.10247
Pages: 5517-5522
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of continuous use of dexmedetomidine during general anesthesia on perioperative levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in patients undergoing radical resection of ovarian cancer was investigated. The initial treatment of ovarian cancer is mainly radical surgery. Most patients with ovarian cancer radical surgery can achieve good results, but the use of improper anesthetic drugs in radical surgery can easily lead to unstable patient vital signs. Therefore, the selection of appropriate anesthetic drugs has become the key to radical ovarian cancer surgery. There are few reports on the use of dexmedetomidine in anesthesia for ovarian cancer radical surgery. This study was performed to retrospectively analyze the case data of patients undergoing laparoscopic ovarian cancer radical surgery, and to compare the hemodynamics of dexmedetomidine anesthesia with midazolam anesthesia and the concentrations of TNF-α and IL-6, to provide reference for clinical implementation of ovarian cancer radical surgery. The hemodynamics of patients in the dexmedetomidine group were stable compared with the midazolam group. Serum TNF-α and IL-6 levels were significantly lower in the dexmedetomidine group than that in the midazolam group. If dexmedetomidine were continuously used during general anesthesia, the perioperative serum levels of TNF-α and IL-6 could be effectively reduced in patients undergoing radical resection of ovarian cancer, and the perioperative stress response was suppressed.

View Figures

View References

1	Salomon-Perzyński A, Salomon-Perzyńska M, Michalski B and Skrzypulec-Plinta V: High-grade serous ovarian cancer: The clone wars. Arch Gynecol Obstet. 295:569–576. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ramachandran SM, Liu LY and Perkins SH: Peristomal nodule patient with ovarian cancer. JAMA. 319:1158–1159. 2018. View Article : Google Scholar : PubMed/NCBI
3	Gallotta V, Cicero C, Conte C, Vizzielli G, Petrillo M, Fagotti A, Chiantera V, Costantini B, Scambia G and Ferrandina G: Robotic versus laparoscopic staging for early ovarian cancer: A case-matched control study. J Minim Invasive Gynecol. 24:293–298. 2017. View Article : Google Scholar : PubMed/NCBI
4	Dong H, Zhang Y and Xi H: The effects of epidural anaesthesia and analgesia on natural killer cell cytotoxicity and cytokine response in patients with epithelial ovarian cancer undergoing radical resection. J Int Med Res. 40:1822–1829. 2012. View Article : Google Scholar : PubMed/NCBI
5	Schaller SJ, Alam SM, Mao J, Zhao Y, Blobner M, Greenblatt DJ and Martyn JA: Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. J Pharm Pharmacol. 69:82–88. 2017. View Article : Google Scholar : PubMed/NCBI
6	Armstrong DK: New therapies for ovarian cancer. J Natl Compr Canc Netw 16 (5S). 632–635. 2018. View Article : Google Scholar
7	Park SJ, Shin S, Kim SH, Kim HW, Kim SH, Do HY and Choi YS: Comparison of dexmedetomidine and fentanyl as an adjuvant to ropivacaine for postoperative epidural analgesia in pediatric orthopedic surgery. Yonsei Med J. 58:650–657. 2017. View Article : Google Scholar : PubMed/NCBI
8	Scibelli G, Maio L, Sasso M, Lanza A and Savoia G: Dexmedetomidine: Current role in burn ICU. Transl Med UniSa. 16:1–10. 2017.PubMed/NCBI
9	Pudenz M, Roth K and Gerhauser C: Impact of soy isoflavones on the epigenome in cancer prevention. Nutrients. 6:4218–4272. 2014. View Article : Google Scholar : PubMed/NCBI
10	Nicula R and Costin N: Management of endometrial modifications in perimenopausal women. Clujul Med. 88:101–110. 2015.PubMed/NCBI
11	Chatterjee M, Hurley LC and Tainsky MA: Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep. 21:37–44. 2017. View Article : Google Scholar : PubMed/NCBI
12	Felix AS, Bower JK, Pfeiffer RM, Raman SV, Cohn DE and Sherman ME: High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. Int J Cancer. 140:555–564. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zambirinis CP and Miller G: Cancer manipulation of host physiology: Lessons from pancreatic cncer. Trends Mol Med. 23:465–481. 2017. View Article : Google Scholar : PubMed/NCBI
14	Brand AH, DiSilvestro PA, Sehouli J and Berek JS: Cytoreductive surgery for ovarian cancer: Quality assessment. Ann Oncol. 28 (Suppl 8):viii25–viii29. 2017. View Article : Google Scholar : PubMed/NCBI
15	Ghodki PS, Sardesai SP and Halikar SS: Dexmedetomidine premedication in cataract surgery under topical anaesthesia: To assess patient and surgeon satisfaction. S Afr J Anaesthesiol Analg. 21:17–21. 2015.
16	Djaiani G, Silverton N, Fedorko L, Carroll J, Styra R, Rao V and Katznelson R: Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. Anesthesiology. 124:362–368. 2016. View Article : Google Scholar : PubMed/NCBI
17	Balk M, Hentschke H, Rudolph U, Antkowiak B and Drexler B: Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices. Sci Rep. 7:3503–3515. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yasoshima Y and Shimura T: Midazolam impairs the retrieval of conditioned taste aversion via opioidergic transmission in mice. Neurosci Lett. 636:64–69. 2017. View Article : Google Scholar : PubMed/NCBI
19	Freeman J and Buggy DJ: Modelling the effects of perioperative interventions on cancer outcome: Lessons from dexmedetomidine. Br J Anaesth. 120:15–17. 2018. View Article : Google Scholar : PubMed/NCBI
20	Li Z and Sheng L: Significance of dynamic evolution of TNF-α, IL-6 and intestinal fatty acid-binding protein levels in neonatal necrotizing enterocolitis. Exp Ther Med. 15:1289–1292. 2018.PubMed/NCBI
21	Kim Y, Lim HJ, Jang HJ, Lee S, Jung K, Lee SW, Lee SJ and Rho MC: Portulaca oleracea extracts and their active compounds ameliorate inflammatory bowel diseases in vitro and in vivo by modulating TNF-α, IL-6 and IL-1β signalling. Food Res Int. 106:335–343. 2018. View Article : Google Scholar : PubMed/NCBI
22	Gupta B, Verma RK, Kumar S and Chaudhary G: Comparison of analgesic efficacy of dexmedetomidine and midazolam as adjuncts to lignocaine for intravenous regional anesthesia. Anesth Essays Res. 11:62–66. 2017. View Article : Google Scholar : PubMed/NCBI
23	Barends CR, Absalom A, van Minnen B, Vissink A and Visser A: Dexmedetomidine versus midazolam in procedural sedation. A systematic review of efficacy and safety. PLoS One. 12:e01695252017. View Article : Google Scholar : PubMed/NCBI
24	Field C and Goff BA: Dermatomyositis - key to diagnosing ovarian cancer, monitoring treatment and detecting recurrent disease: Case report. Gynecol Oncol Rep. 23:1–3. 2017. View Article : Google Scholar : PubMed/NCBI